I will here. I Completely overlooked the April 15th PR.
VANCOUVER, BC / ACCESSWIRE / April 10, 2015 / Pacific Therapeutics Ltd. (CNSX: PT) (OTC:PCFTF) (1P3.F) (the "Company") is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing approved drugs for large markets.
The Company is pleased to announce that the United States Patent Office (PO) has issued a Notice Of Allowability for the Company's patent application, Compositions and Methods for Treating fibroproliferative Disorders.
Doug Unwin, CEO and President of the Company stated "this is a huge milestone for the Company as it adds additional protection to our already issued patents for the technology in PTL-202 our lead candidate for pulmonary and of the fibrotic diseases."
The Company's lead drug candidate for fibrosis (progressive scarring of the organ), PTL-202 is a combination of Pentoxifylline (a FDA approved drug used for treating leg cramps) and an amino acid and an extremely potent and important antioxidant. The positive results from the phase 1 clinical trial of PTL-202 and pre-clinical results, will lead to further development of the product for treating fibrosis such as Idiopathic Pulmonary Fibrosis and Liver Cirrhosis.
Market Data 
Markets 
